TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03402334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient counseling for HCV associated CVD risk factors
Description: Patients will be counseled for cardiovascular disease risk factors associated with Hepatitis C infection. Such risk factors include atherosclerosis, heart attack, and stroke. Cardiovascular risk factors can be managed through connection with primary care and reduced through curative HCV treatment.
Study: NCT01422161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin commonly known as BOTOX®
Description: A total dose between 200-300 units of Botulinum toxin will be administered across 12 muscles of the affected hand.~There will be 1 treatment cycle during the 9 week study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will receive a placebo injection.
Study: NCT01129622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole (12.5 mg/day ) which is higher than the dose routinely used for therapeutic indications is given for a brief duration (3 successive days) aiming to promote acute aromatase inhibition suitable for pre-diagnostic regimens.
Study: NCT03901144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% urea/20% glycerol cream
Description: Moisturizing cream for topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miniderm® 20% cream
Description: Moisturizing cream for topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprobase® cream
Description: Emollient cream for topical application
Study: NCT01486875

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted, and administered subcutaneously (under the skin) once or twice daily
Study: NCT00960375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BTSCS
Description: BTSCS lasts 3 months, includes two 60-minute group meetings per week (24 group meetings total), and is delivered in small groups of 4-8 participants run by a trained interventionist. BTSCS includes: (1) An individual motivational enhancement meeting during the first week of treatment to help participants think about individual reasons for smoking cessation; (2) Breath carbon monoxide monitoring and goal-setting at the beginning of each meeting; (3) Skills for reducing smoking; (4) Social Skills Training; (5) Education about the biology of SPMI and smoking and the physiological harm caused by smoking; (5) Relapse prevention training; (6) Education about and assistance with nicotine replacement therapy for participants who are interested in learning about and trying it.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: StSST
Description: The StSST program is adapted from a 9-session weekly smoking cessation group program developed at the Outpatient Research Program of the Maryland Psychiatric Research Center and designed for people with schizophrenia. In this study, the StSST program meet twice per week for 3 months (24 sessions total). Participants complete a breath carbon monoxide (CO) test at the start of each group. StSST groups provide education about smoking and support for quitting.
Study: NCT03844776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-Amoxiclav
Description: amoxicillin + clavulanic acid orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-Amoxiclav
Description: amoxicillin + clavulanic acid orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-Amoxiclav
Description: amoxicillin + clavulanic acid orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: paracetamol orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: paracetamol orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: 0.2% chlorhexidine mouthwash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: 0.2% chlorhexidine mouthwash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: 0.2% chlorhexidine mouthwash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 0.9% normal saline irrigation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 0.9% normal saline irrigation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 0.9% normal saline irrigation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 500 Mg
Description: Amoxicillin 500 orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: metronidazole 500 mg orally
Study: NCT01847352

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous administration of ferric carboxymaltose
Description: Intravenous administration of ferric carboxymaltose 15mg/kg up to a maximum dose of 1000mg

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous administration of ferric carboxymaltose
Description: Intravenous administration of ferric carboxymaltose 15mg/kg up to a maximum dose of 1000mg

Intervention type: OTHER
Group type: OTHER
Intervention: Subacute hypoxic exposures
Description: Exposure to six hours of isocapnic hypoxia with end-tidal partial pressure of oxygen clamped at 55 Torr, with and without prior iron infusion

Intervention type: OTHER
Group type: OTHER
Intervention: Subacute hypoxic exposures
Description: Exposure to six hours of isocapnic hypoxia with end-tidal partial pressure of oxygen clamped at 55 Torr, with and without prior iron infusion
Study: NCT04362436

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TheraSpheres Selective Internal Radiation Therapy (SIRT)
Description: Single-photon emission computed tomography (SPECT) imaging will assess 99mTc-MAA (MAA being macro aggregated albumin) deposition in the tumour bed to estimate the dose of radiation to tumour and healthy tissue, before administration of TheraSpheres to eligible patients
Study: NCT02113917

Intervention type: BIOLOGICAL
Intervention: Identification of biological markers
Study: NCT04353973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care with a Genetic Counselor either In-Person or by Remote Services (Telephone or Video Conferencing)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care with a Genetic Counselor either In-Person or by Remote Services (Telephone or Video Conferencing)
Study: NCT00689390

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Boceprevir
Description: In previous treatment studies, boceprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Narlaprevir
Description: In previous treatment studies, narlaprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Peginterferon alfa-2b
Description: In previous treatment studies, peginterferon alfa-2b was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Peginterferon alfa-2b
Description: In previous treatment studies, peginterferon alfa-2b was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).

Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: In previous treatment studies, ribavirin was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).

Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: In previous treatment studies, ribavirin was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).

Intervention type: OTHER
Group type: OTHER
Intervention: Blood/Plasma Collection
Description: Blood samples were collected at all visits during the LTFU for blood chemistry and hematology. Plasma samples were collected at all visits as appropriate from participants who were sustained responders at the end of FU in the previous treatment protocol for HCV-RNA PCR and HCV sequence analysis.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood/Plasma Collection
Description: Blood samples were collected at all visits during the LTFU for blood chemistry and hematology. Plasma samples were collected at all visits as appropriate from participants who were sustained responders at the end of FU in the previous treatment protocol for HCV-RNA PCR and HCV sequence analysis.
Study: NCT02245477

Intervention type: DEVICE
Intervention: obstetric Ultrasound
Description: Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.

Intervention type: OTHER
Intervention: serum Vascular Endothelial Growth Factor
Description: Maternal blood samples (10 cc) were taken from an antecubital vein. Plastic clean sterile tubes were used for collection of blood. Two cc of the blood sample were put in other clean sterile tubes containing ethylene diamine tetra-acetic acid (EDTA) to be used in measuring maternal hemoglobin concentrations and evaluating the complete blood count. The rest of maternal blood samples were centrifuged within 3 hours and sera collected equally in 2 suitable containers and stored at -80 degrees until assayed (first container for routine laboratory investigations and the second for VEGF assay).VEGF sample was allowed to clot for 30 minutes before centrifugation for 15 minutes. Serum is removed and assay immediately or sample was stored at -80 degrees
Study: NCT03215017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transanal irrigation
Description: Effect of Transanal irrigation (TAI) using Peristeen® anal irrigation system - Coloplast
Study: NCT04353973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care with a Genetic Counselor either In-Person or by Remote Services (Telephone or Video Conferencing)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-Test Intervention
Description: Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-Test Intervention
Description: Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
Study: NCT02436473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 1150ppm F
Description: US marketed toothpaste containing 1150ppm of F

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Toothpaste containing 0ppm F
Description: Experimental toothpaste containing 0ppm F

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste containing 250ppm F
Description: Experimental toothpaste containing 250ppm F

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste containing 1150ppm F
Description: Experimental toothpaste containing 1150ppm F
Study: NCT01263665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25 cm GORE® VIABAHN®
Description: 25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, possibly in conjunction with an additional overlapping VIABAHN® device (2.5, 5, 10, 15, or 25 cm lengths) based on the enrolled patient's lesion length (greater than or equal to 20 cm length).
Study: NCT03215017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication
Description: Medication to help control of the bowel movement (One or a combination of Loperamide, Sorbitol, Sterculia gum)
Study: NCT05112575

Intervention type: RADIATION
Intervention: Postoperative imaging with magnetic resonance imaging or computed tomography
Description: Postoperative imaging control with magnetic resonance or computed tomography after craniotomy for vascular or neurooncological operations.

Intervention type: RADIATION
Intervention: Postoperative imaging with magnetic resonance imaging or computed tomography
Description: Postoperative imaging control with magnetic resonance or computed tomography after craniotomy for vascular or neurooncological operations.
Study: NCT04386200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web-based thecnologies
Description: Integration of traditional face-to-face educational approach with web-based technologies.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: traditional approach
Description: traditional face-to-face educational approach
Study: NCT02823769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SI-R21204 resin composite
Description: Primary caries of posterior teeth will be restored using SI-R21204 resin composite. Procedures will be done under local anesthesia if necessary. The preperation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nanohybrid resin composite
Description: One of the cavities will be restored with a nanohybrid resin composite (Clearfil Majesty) as a control restoration wth ordinary restorative techniques.
Study: NCT01336933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralatrexate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: comparative genomic hybridization
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Description: Correlative studies
Study: NCT03767621

Intervention type: OTHER
Intervention: Indication of revascularization
Description: Device: iFR/FFR
Study: NCT03839368

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fixation of angle fracture
Description: open reduction and internal fixation of angle fracture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fixation of angle fracture
Description: open reduction and internal fixation of angle fracture
Study: NCT02641847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel

Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin or epirubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin or epirubicin

Intervention type: DRUG
Group type: OTHER
Intervention: doxorubicin or epirubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study: NCT02316730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanchi-Tongshu Capsule (Enteric coated pellets)
Description: Take 0.7g (2 Capsules) of test preparation orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sanchi-Tongshu Capsule
Description: Take 0.4g (2 Capsules) of reference preparation orally.
Study: NCT03034486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D930, D565
Description: Period 1: D565 administered 1 time for one day/ Period 2: D930 administered 3 time per day for 9 days/ Period 3: D565(1 time per day) with D930(3 time per day) administered for 9days
Study: NCT02611973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aspirin therapy interruption
Description: Stop the treatment by aspirin 100mg/d in the experimental arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual treatment by aspirin 100 mg/d in the active comparator arm
Description: HU+ aspirin maintenance

Intervention type: OTHER
Group type: OTHER
Intervention: No interruption of aspirin in the Observational arm
Description: patient with Contre indication to aspirin or required antithrombotic therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxyurea treatment (HU)
Description: HU maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea treatment (HU)
Description: HU maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment (HU)
Description: HU maintenance
Study: NCT00525512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium 18 mcg
Description: Oral inhalation once daily of 18mcg tiotropium via handihaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral inhalation of once-daily placebo matching tiotropium via handihaler
Study: NCT01239511

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: green tea polyphenols (STA-2)
Description: 2 capsules t.i.d., after meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: green tea polyphenols (STA-2)
Description: 2 capsules t.i.d., after meal
Study: NCT00699894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant 40 mg
Description: aprepitant 40 mg PO 1-3 hours prior to surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron 4 mg
Description: ondansetron 4 mg IV 2-5 minutes prior to induction of anesthesia
Study: NCT04100031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bandage contact lenses
Description: wear bandage contact lensesfor a week after cataract surgery.
Study: NCT01239511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: green tea polyphenols (STA-2)
Description: 2 capsules t.i.d., after meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: green tea polyphenols (STA-2)
Description: 2 capsules t.i.d., after meal
Study: NCT02374749

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self-assessment/self-management
Description: Nurse led-program of self-assessment/ self-management of spondyloarthritis

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comorbidities (detection/prevention)
Description: Standardized assessment of comorbidities by nurses
Study: NCT04258423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Low dose Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus
Study: NCT02584946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avenanthramides
Description: AVAs are a group of diphenolic acids that are found only in oats (Avena sativa).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Avenanthramides
Description: AVAs are a group of diphenolic acids that are found only in oats (Avena sativa).
Study: NCT03142386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Study: NCT00321789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: spouse-assisted intervention
Description: Couples assigned to this arm received nine monthly phone calls from a nurse. The patient created monthly goals and action plans related to diet, exercise, patient-provider communication, or medication adherence. The spouse created plans to support patient goal achievement.
Study: NCT02511379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propylene Glycol 0.6% eye drops
Study: NCT05256485

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy,mindfulness based relapse prevention,twelve-step therapy
Description: In cognitive-behavioral therapy, participants learned that thoughts and emotions contribute to behavior, and responses to thoughts and emotions can be controlled.~in mindfulness-based relapse prevention, participants learned to focus on the present moment experience including craving with an attitude of acceptance and non-judging.~In twelve-step therapy, participants learned principles of acceptance, gratitude, forgiveness, tolerance, patience, humility, and honesty together with participation in different healthy ways to enrich life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy,mindfulness based relapse prevention,twelve-step therapy
Description: In cognitive-behavioral therapy, participants learned that thoughts and emotions contribute to behavior, and responses to thoughts and emotions can be controlled.~in mindfulness-based relapse prevention, participants learned to focus on the present moment experience including craving with an attitude of acceptance and non-judging.~In twelve-step therapy, participants learned principles of acceptance, gratitude, forgiveness, tolerance, patience, humility, and honesty together with participation in different healthy ways to enrich life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy,mindfulness based relapse prevention,twelve-step therapy
Description: In cognitive-behavioral therapy, participants learned that thoughts and emotions contribute to behavior, and responses to thoughts and emotions can be controlled.~in mindfulness-based relapse prevention, participants learned to focus on the present moment experience including craving with an attitude of acceptance and non-judging.~In twelve-step therapy, participants learned principles of acceptance, gratitude, forgiveness, tolerance, patience, humility, and honesty together with participation in different healthy ways to enrich life.